MAIA Biotechnology, Inc. MAIA 深 滬
交易中 03-25 10:59:55 美东时间
1.485
+0.045
+3.13%
華盛通- 最 高1.495
- 今 開1.475
- 成交量 10.25万股
- 最 低 1.455
- 昨 收 1.44
- 總市值 8710.95万
- 52周最高 3.19
- 市盈率 靜 --
- 換手率 0.17%
- 52周最低 0.87
- 委 比 66.22%
- 總股本 5865.96万
- 歷史最高 9.64
- 量 比 1.06
- 振 幅 2.78%
- 歷史最低 0.82
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 33.33 percent increase over losses of $(0.12) per share from
03-24 06:11
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Edesa Biotech (NASDAQ:EDSA) shares rose 61.0% to $3.67 during Tuesday'...
03-04 01:05
MAIA Biotechnology Highlights Phase 3 Momentum And FDA Fast Track For Ateganosine In Third-Line NSCLC
Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysisFDA Fast Track designation offers clear pathway for ateganosine as third-line therapy
02-24 21:47
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Nuwellis (NASDAQ:NUWE) shares rose 81.5% to $3.9 during Tuesday's regu...
01-28 01:05
MAIA Biotechnology Announces Milestones And Growth Catalysts For 2026; Initial Measures Of Efficacy From Phase 3 Study, Conclusion Of Part C Of Phase 2 Study, Engage In Regulatory Interactions With The FDA, Clinical Development Of Second-generation Molecules To Start In Phase 1 Trials
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a corporate update on 2025 achievements
01-20 23:25
MAIA Biotechnology announces $1.51M private placement
MAIA Biotechnology (NYSE:MAIA) announced on Tuesday that it has entered into definitive agreements for the purchase and sale of an aggregate of 1.23M shares of common stock at a price of $1.224 per s...
2025-12-17 05:33
MAIA Biotechnology Doses First Patient In Phase 3 Trial Of Ategenosine Plus Checkpoint Inhibitor For Advanced NSCLC
Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapyCHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- MAIA
2025-12-11 22:10
MAIA Biotechnology Makes Open-Market Purchases: CEO Buys 94,300 Shares At An Average Price Of $1.08/Share; Board Members Acquire 88,145 Shares At An Average Price Of $1.04/Share, Totaling 182,445 Shares Combined
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and certain members of the
2025-12-01 22:20
MAIA Biotechnology Highlights Phase 2 THIO‑101 Expansion And Phase 3 THIO‑104 Trials Of Telomere Targeting Agent Ateganosine For NSCLC At SITC 2025; FDA Grants Fast Track Designation
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countriesPosters for Phase 2 and Phase 3 clinical trials availableCHICAGO , Nov. 21, 2025 (GLOBE NEWSWIRE) -- MAIA
2025-11-21 22:05
MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
MAIA Biotechnology announced the enrollment of five patients from Taiwan and Turkey in the expansion phase of its THIO-101 Phase 2 clinical trial, which evaluates ateganosine in combination with immune checkpoint inhibitors for advanced NSCLC patients resistant to prior therapies. The trial is ongoing across multiple continents, allowing access to a larger patient population. Dr. Saadettin Kiliçkap highlighted the potential of ateganosine to addr...
2025-10-27 14:45
